OLMESARTAN MEDOXOMIL

Olmesartan medoxomil is a prodrug ARB offering improved bioavailability for hypertension control. Side effects include hypotension, GI symptoms, and renal function changes. Only GMP materials will be supplied, logistics all according to GDP.

SKU: dcc1d5f988f7 Category: Tag:

Product Description


Mechanism of Action

OLMESARTAN MEDOXOMIL shows a complex, multipathway biochemical interaction profile involving modulation of enzymeregulated catalytic cycles, receptorlevel signalling networks, intracellular ion dynamics, mitochondrial respiratory control, redoxbalance adaptation, cytoskeletal organisation and transcriptionfactor regulatory behaviour. Its physicochemical structure supports direct or indirect interaction with catalytic residues, allosteric pockets, membranespanning receptors, signalling intermediates and structural proteins, enabling influence over secondmessenger pathways (Ca²⁺, cAMP, IP, DAG), phosphorylation kinetics, ROS generation and mitochondrial ATPsynthesis efficiency.

Depending on concentration, exposure duration and biological substrate, OLMESARTAN MEDOXOMIL may shift metabolic routing, alter vesicular transport, influence chromatin accessibility, modify transcriptional clusters, or recalibrate mitochondrial stressresponse thresholds across diverse experimental models.

Benefits and Advantages

Common applications in research environments include:

  • Highresolution receptorligand interaction analysis and molecular docking validation
  • Enzymekinetic dissection and catalyticpathway reconstruction
  • Mitochondrialperformance assays, redoxstress modelling and ATPflux quantification
  • Multiomics integration: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletaldynamics studies involving actin, tubulin and membranetension regulation
  • Apoptosis, autophagy, necroptosis, ferroptosis and stressresponse pathway mapping
  • SAR (structureactivity relationship) investigation and molecularoptimisation workflows
  • Preclinical pharmacodynamic modelling and mechanistic doseresponse assays

Side Effects and Risks

Potential laboratoryobserved risks include:

  • ROS accumulation and oxidativestress imbalance
  • Mitochondrial hyperactivation or respiratorychain suppression
  • Disruption of Ca²⁺/Na⁺/K⁺ ionic homeostasis and ionchannel behaviour
  • Unintended receptor crossactivation or inhibitory interference
  • Cytoarchitectural destabilisation, membrane fragility or impaired trafficking
  • Dosedependent cytotoxicity and activation of apoptosis/autophagy signalling
  • Transcriptional and epigenetic instability under prolonged exposure
  • Inflammatory pathway activation (NF-κB, MAPK, JNK)

Use exclusively under controlled laboratory conditions, following strict biosafety and handling protocols.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C29H30N6O6

Molecular Weight

558.6 g/mol

CAS Number

144689-63-4

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Olmesartan medoxomil; 144689-63-4; Benicar; Olmetec; CS-866

IUPAC/Chemical Name

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

InChl Key

UQGKUQLKSCSZGY-UHFFFAOYSA-N

InChl Code

InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

References

https://pubchem.ncbi.nlm.nih.gov/compound/130881;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download